FR 104

Drug Profile

FR 104

Alternative Names: Anti CD28 monoclonal antibody - OSE Therapeutics; FR-104

Latest Information Update: 20 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Effimune
  • Developer Biomedical Primate Research Center; Janssen Biotech; OSE Immunotherapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action CD28 antigen inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Transplant rejection
  • Preclinical Encephalomyelitis; Multiple sclerosis; Psoriasis; Uveitis

Most Recent Events

  • 26 Sep 2017 OSE Immunotherapeutics plans a phase II trial for Rheumatoid arthritis in late 2018
  • 05 Jul 2016 Janssen Biotech exercised the global option and license agreement for the development and commercialisation of FR 104
  • 01 Jul 2016 Phase-II clinical trials in Rheumatoid arthritis (IV) (OSE ImmunoTherapeutics pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top